Microbiome Consumer Nutrition Congress | Kisaco Research

San Francisco, CA, USA
24-25 September, 2019

We are co-located with the 6th Skin Microbiome Congress global series, to visit their website, click the link.

Why Attend

Welcome to the Microbiome Consumer Nutrition Congress

The global probiotics market is expected to be worth $64 Bn by 2024, an increase of $20bn from 2017. Rising consumer consciousness around personal healthcare and diet coupled with substantial improvements in R&D is fueling a new wave of products that promote human gut health and wellbeing.

Whether you’re developing foods, beverages, nutritional supplements, pre- / pro- biotics or infant formulas, join our network of leading nutrition and consumer goods companies, food and nutritional supplement start-ups, ingredients suppliers, formulation experts, entrepreneurs and leading academics to address the challenges and opportunities of developing the next generation of gut health products.

The Microbiome Consumer Nutrition Congress connects science and business in the pre-/pro-biotic and microbiome fields to transform microbiome R&D into successful and effective consumer products. 

Also on-site will be our 2nd Skin Microbiome West Coast Congress, individual as well combined tickets will be available.

Who Will Be There

35%
Independent Nutrition Companies
10%
Investors
25%
Multinational Nutrition and Consumer Health Companies
15%
Ingredients and Product Forumlators
10%
Retailers
5%
Nutritionists

Independent Nutrition Companies

Investors

Multinational Nutrition and Consumer Health Companies

Ingredients and Product Forumlators

Retailers

Nutritionists

The Speakers

 

Dr. Sabine Hazan

Founder/CEO
ProgenaBiome, Ventura Clinical Trials

Dr. Sabine Hazan, acclaimed Gastroenterologist and founder of ProgenaBiome, LLC, Ventura Clinical Trials, LLC, and Malibu Specialty Center, is at the forefront of medicine. She recently turned her focus from doing Fecal Microbiota Transplant, also known as FMT to better understand the microbiome. FMT is the process of recolonizing the gut with good flora in hopes to cure specific disease. Spearheading advancement in medicine, this treatment is being explored by Dr. Hazan following the leadership of Dr. Thomas Borody and the late Dr.

Dr. Sabine Hazan

Founder/CEO
ProgenaBiome, Ventura Clinical Trials

Dr. Sabine Hazan

Founder/CEO
ProgenaBiome, Ventura Clinical Trials

Dr. Sabine Hazan, acclaimed Gastroenterologist and founder of ProgenaBiome, LLC, Ventura Clinical Trials, LLC, and Malibu Specialty Center, is at the forefront of medicine. She recently turned her focus from doing Fecal Microbiota Transplant, also known as FMT to better understand the microbiome. FMT is the process of recolonizing the gut with good flora in hopes to cure specific disease. Spearheading advancement in medicine, this treatment is being explored by Dr. Hazan following the leadership of Dr. Thomas Borody and the late Dr. Sydney Finegold to treat Crohn’s disease, Celiac disease, Alzheimer’s disease, Alopecia areata, Autism, Obesity, Metastatic cancer, and recurrent infection with Clostridium difficile.  She is a firm believer in the potential to recolonize your gut back to health recognizing that much work is still left to be done.

Well-prepared for these endeavors, Dr. Hazan was the first woman accepted in to the University of Florida as a Clinical Gastroenterology Fellow, and has continued to be a pioneer in medicine. She has over 22 years of experience in clinical trials and has also been published in numerous medical journals. In the past year, she has served as the series editor for the journal Practical Gastroenterology, for a series on the microbiome. As a trailblazer from the start, she believes in using logic when practicing medicine and tries to think outside the box. “I always remind myself that much like every fingerprint is different, every patient’s symptom is different, and one cannot practice like a robot.”

 

Alan Murray

CEO
Goodbelly

Alan Murray

CEO
Goodbelly

Alan Murray

CEO
Goodbelly
 

Aubrey Levitt

CEO
Postbiotics Plus

Aubrey is the co-founder of Postbiotics Plus, a microbiome start-up researching adjunct therapies that protect the gut from assault. 

She previously founded a tonic and elixir company, Body + Eden, which was featured in Oprah Magazine, Elle, Well & Good and Japan Vogue and partnered with brands such as One & Only Resorts, Wallpaper Handmade, and The Tracy Anderson Method.

Aubrey Levitt

CEO
Postbiotics Plus

Aubrey Levitt

CEO
Postbiotics Plus

Aubrey is the co-founder of Postbiotics Plus, a microbiome start-up researching adjunct therapies that protect the gut from assault. 

She previously founded a tonic and elixir company, Body + Eden, which was featured in Oprah Magazine, Elle, Well & Good and Japan Vogue and partnered with brands such as One & Only Resorts, Wallpaper Handmade, and The Tracy Anderson Method.

Aubrey speaks often about gut health and the microbiome, and has created courses for nutrition schools. She holds a BA from Boston University in Advertising and won an award for best women’s health resource while at Grey Healthcare. She also holds an MFA in creative writing and has been a guest lecturer on product adoption at the New School.

 

Ben Goodwin

CEO
OLIPOP

Ben Goodwin is a Californian based product developer and entrepreneur who specializes in digestive/microbiome health and increasing the broad accessibility and scientific rigor of health oriented Consumer Packaged Goods. Now on his third digestive-health beverage venture OLIPOP, Ben has been a product formulator for over a decade with a specific focus on fiber/prebiotics, probiotics and scaled fermentation systems.

Ben Goodwin

CEO
OLIPOP

Ben Goodwin

CEO
OLIPOP

Ben Goodwin is a Californian based product developer and entrepreneur who specializes in digestive/microbiome health and increasing the broad accessibility and scientific rigor of health oriented Consumer Packaged Goods. Now on his third digestive-health beverage venture OLIPOP, Ben has been a product formulator for over a decade with a specific focus on fiber/prebiotics, probiotics and scaled fermentation systems.

Ben’s passion for mass microbiome health stems from his own background making healthier dietary decisions as a teenager and the benefits he experienced in both his physical and mental health as a result. His life mission is oriented around increasing the accessibility and desirability of healthy packaged goods, and believes in a future where mass processed foods are as tasty as they are fundamentally healthy for the average person. In addition to health and wellness, Ben also has been DJing for over a decade and runs the electronic music site FWD.DJ.

For more information please see drinkolipop.com

 

Caroline Beckman

CEO
Nouri

Caroline Beckman is an American entrepreneur who began her career in the health industry during her teenage years. At 18 years old she joined Suja Juice, one of the fastest growing beverage brands in history, as a founding employee. After dropping out of university to pursue further health research, she was backed by tech entrepreneur, founder of PayPal, and first investor in Facebook, Peter Thiel. Currently 25 years old, Caroline has founded, advised and invested in over 10 food and beverage companies.

Caroline Beckman

CEO
Nouri

Caroline Beckman

CEO
Nouri

Caroline Beckman is an American entrepreneur who began her career in the health industry during her teenage years. At 18 years old she joined Suja Juice, one of the fastest growing beverage brands in history, as a founding employee. After dropping out of university to pursue further health research, she was backed by tech entrepreneur, founder of PayPal, and first investor in Facebook, Peter Thiel. Currently 25 years old, Caroline has founded, advised and invested in over 10 food and beverage companies.

Caroline is excited to now introducing her new venture Nouri, a biotechnology company created to increase mental and physical health globally. Nouri is focused on innovating and delivering clinically-supported solutions to gut and brain health. Nouri's first consumer product line delivers proprietary probiotic blends encapsulated within plant-based omegas 3,6, and 9 (Ahiflower oil).

 

Colleen Cutcliffe

CEO and Co-Founder
Whole Biome

Colleen Cutcliffe is a Biochemist and Molecular Biologist with 10 years of experience managing and directing fundamental biology research teams in the academic, pharmaceutical and biotech sectors. Prior to co-founding Whole Biome, Colleen served as the Senior Manager of Biology at Pacific Biosciences where she met and collaborated with her fellow co-founders, John and Jim. Before her role at Pacific Biosciences, Colleen served as a Scientist in the Parkinson's Disease discovery group at Elan Pharmaceuticals.

Colleen Cutcliffe

CEO and Co-Founder
Whole Biome

Colleen Cutcliffe

CEO and Co-Founder
Whole Biome

Colleen Cutcliffe is a Biochemist and Molecular Biologist with 10 years of experience managing and directing fundamental biology research teams in the academic, pharmaceutical and biotech sectors. Prior to co-founding Whole Biome, Colleen served as the Senior Manager of Biology at Pacific Biosciences where she met and collaborated with her fellow co-founders, John and Jim. Before her role at Pacific Biosciences, Colleen served as a Scientist in the Parkinson's Disease discovery group at Elan Pharmaceuticals. Colleen completed her postdoctoral research under Elizabeth Perlman at Children's Memorial Hospital in Chicago, IL, her Ph.D in Biochemistry and Molecular Biology under Cecile Pickart at Johns Hopkins University and her B.A. in Biochemistry from Wellesley College.

 

Dale Pfost

CEO
MicroBiome Therapeutics

Dale Pfost, PhD, has 35 years of experience as an entrepreneur, investor and business executive. His areas of expertise include biotechnology, high-tech, corporate strategy and corporate governance. Dale has been the founding CEO of five biotechnology companies, three of which became publicly traded with valuations of over $2 billion. Dale has successfully completed 22 financings with dollar totals in the hundreds of millions. He has overseen M&A deals for nine companies and served as a director at multiple public and private firms. 

Dale Pfost

CEO
MicroBiome Therapeutics

Dale Pfost

CEO
MicroBiome Therapeutics

Dale Pfost, PhD, has 35 years of experience as an entrepreneur, investor and business executive. His areas of expertise include biotechnology, high-tech, corporate strategy and corporate governance. Dale has been the founding CEO of five biotechnology companies, three of which became publicly traded with valuations of over $2 billion. Dale has successfully completed 22 financings with dollar totals in the hundreds of millions. He has overseen M&A deals for nine companies and served as a director at multiple public and private firms. 

Dale was recently the US-based General Partner at Advent Life Sciences, a leading life sciences venture capital fund in London, and is the acting CEO of a microbiome company, Microbiome Therapeutics. Dale has extensive experience in successfully growing early-stage companies to exits via trade-sales or IPO, including Infinitek/Biomek (sold to SmithKline Beckman), Oxford GlycoSciences (eventual IPO), Orchid BioSciences (IPO), Acuity Pharmaceuticals (reverse merger to form OPKO Heath), Receptor BioLogix (sold to Symphogen). 

He has served as a director at about 10 private and public firms, is the co-author of multiple scientific papers and an inventor on 10 patents. Dale has been active in supporting angel investors and local life science start-ups. He earned a BS degree from the University of California, Santa Barbara and a PhD in physics from Brown University. He has homes in New Orleans and Los Altos, California, and holds a private pilot license.

 

David Crean

Managing Director
Objective Capital Partners

David H. Crean, Ph.D is a Managing Director at Objective Capital Partners where he leads the firm’s life science investment banking transactions. Dr. Crean has in excess of 20 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. David’s transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital raising activities.

David Crean

Managing Director
Objective Capital Partners

David Crean

Managing Director
Objective Capital Partners

David H. Crean, Ph.D is a Managing Director at Objective Capital Partners where he leads the firm’s life science investment banking transactions. Dr. Crean has in excess of 20 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. David’s transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital raising activities. He has supported company and client engagements in both U.S. domestic and foreign transactions including Japan, China and Europe.

Prior to joining Objective Capital Partners, Dr. Crean served over 20 years in specialty pharmaceuticals; namely at Allergan (NYSE:AGN) and Aqua Pharmaceuticals, a private equity-backed company, prior to being sold to Almirall, SA. (BME:ALM). Dr. Crean has led transaction execution in a wide range of specialty areas including aesthetic and therapeutic dermatology, OTC skin care, neurological disorders / CNS, pain, inflammation, ophthalmology, oncology and diagnostics/ detection. His corporate pharmaceutical experience spans research and development expertise in small molecules, biologics, prescription drugs, OTC products and medical devices.

Dr. Crean’s pharmaceutical and biotechnology leadership experience includes serving in key leadership roles in the development and/or growth of many commercial portfolios including: BOTOX, LUMIGAN, JUVEDERM, LATISSE, ACZONE, TAZORAC, MONODOX, FLUOROPLEX, XOLEGEL and VERDESO. Concurrent with Objective Capital, Dr. Crean serves as a strategic business advisor for several life science companies, is an active member on BIOCOM’s Capital Development Committee and BIO International 2017 Partnering Committee and a contributing member on the Membership & Program Committees for the Association for Corporate Growth (ACG) in San Diego.

Dr. Crean holds a Masters of Business Administration Degree with a finance concentration from Pepperdine University School of Management. Additionally, he holds a Doctorate of Philosophy Degree in Biophysics and a Masters of Science Degree in Oncology from the State University of New York at Buffalo. Dr. Crean also earned a Bachelor of Science Degree in Biology from Canisius College.

Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Representative of BA Securities LLC, Member FINRA SIPC.

 

David Gauger

President & Creative Director
Guager Associates

David Gauger is co-founded of Gauger + Associates, a marketing communications firm headquartered in San Francisco, California. The firm provides strategic planning, branding, package design, interactive marketing, content creation and advertising programs for a wide variety of visionary businesses. Much of the Agency’s work is for CPG and ingredient manufacturers in the health and wellness sector.

David Gauger

President & Creative Director
Guager Associates

David Gauger

President & Creative Director
Guager Associates

David Gauger is co-founded of Gauger + Associates, a marketing communications firm headquartered in San Francisco, California. The firm provides strategic planning, branding, package design, interactive marketing, content creation and advertising programs for a wide variety of visionary businesses. Much of the Agency’s work is for CPG and ingredient manufacturers in the health and wellness sector.

David has taught Green & Social Marketing, Advertising, Graphic Design and Advanced Visual Communications at the university level. His agency’s work has garnered hundreds of creative awards in the US, Europe and Asia.

 

David Kyle

Chairman of the Board, Chief Scientific Officer
Evolve Biosystems

Talk to me about… your research 

I am the Chairman and CSO of Evolve Biosystems Inc and a 30-year veteran of biotech having co-founded a range of successful biotech companies in the fields of nutrition and health. These include Martek Biosciences that focuses on DHA and ARA nutrition for infants, which was acquired by DSM in 2011 for $1.1 Billion and Evolve BioSystems the leader in the field of the infant microbiome. I am trained as a biochemist and have spent most of my career working with mothers and babies, focusing specifically on infant nutrition.

David Kyle

Chairman of the Board, Chief Scientific Officer
Evolve Biosystems

David Kyle

Chairman of the Board, Chief Scientific Officer
Evolve Biosystems

Talk to me about… your research 

I am the Chairman and CSO of Evolve Biosystems Inc and a 30-year veteran of biotech having co-founded a range of successful biotech companies in the fields of nutrition and health. These include Martek Biosciences that focuses on DHA and ARA nutrition for infants, which was acquired by DSM in 2011 for $1.1 Billion and Evolve BioSystems the leader in the field of the infant microbiome. I am trained as a biochemist and have spent most of my career working with mothers and babies, focusing specifically on infant nutrition.

Talk to me about…something people may not know about you

 I am the named inventor on over 250 patents and was inducted into the US Technology Hall of Fame in 200 for my contributions to Science and Industry. I am passionately engaged in bringing new technologies into commerce to improve the life-long health trajectory of all infants worldwide

 

Garrett Ruhland

CEO
Biomarker Labs

Garrett Ruhland

CEO
Biomarker Labs

Garrett Ruhland

CEO
Biomarker Labs
 

Grégory Lambert

CEO & VP, R&D
TargEDys SA

Grégory Lambert’s career has been split between biotech and pharma as VP of R&D and CSO in companies such as Novagali Pharma (now Santen) and Septodont. His responsibilities have included innovation, CMC, pre-clinical and clinical development in both Europe and North America.

Grégory Lambert

CEO & VP, R&D
TargEDys SA

Grégory Lambert

CEO & VP, R&D
TargEDys SA

Grégory Lambert’s career has been split between biotech and pharma as VP of R&D and CSO in companies such as Novagali Pharma (now Santen) and Septodont. His responsibilities have included innovation, CMC, pre-clinical and clinical development in both Europe and North America. Grégory also has experience managing IP, business development and general management.  He is an inventor on more than 20 patents, he was involved in the IPO of Novagali Pharma and he has driven the development of several pharmaceutical products from the laboratory through to market authorisation. In 2014, Gregory joined the scientific founders of TargEDys as CEO to setup the business plan and start operations, so far has raised over 10M€ in a mixture of grant and VC funding and begins human clinical trials this year.

 

José Carlos Garcia Garcia

Principal Scientist
P&G

José Carlos Garcia Garcia

Principal Scientist
P&G

José Carlos Garcia Garcia

Principal Scientist
P&G
 

Justin Sonnenburg

Associate Professor
Stanford University

Dr. Sonnenburg's lab is interested in the basic principles that govern interactions within the intestinal microbiota and between the microbiota and the host. To pursue these aims, they colonize germ-free (gnotobiotic) mice with simplified, model microbial communities, apply systems approaches (e.g. functional genomics), and use genetic tools for the host and microbes to gain mechanistic insight into emergent properties of the host-microbial super-organism.

Justin Sonnenburg

Associate Professor
Stanford University

Justin Sonnenburg

Associate Professor
Stanford University

Dr. Sonnenburg's lab is interested in the basic principles that govern interactions within the intestinal microbiota and between the microbiota and the host. To pursue these aims, they colonize germ-free (gnotobiotic) mice with simplified, model microbial communities, apply systems approaches (e.g. functional genomics), and use genetic tools for the host and microbes to gain mechanistic insight into emergent properties of the host-microbial super-organism.

 

Kara Bortone

Head of JLABS San Diego
JLABS, Johnson & Johnson

Kara Bortone

Head of JLABS San Diego
JLABS, Johnson & Johnson

Kara Bortone

Head of JLABS San Diego
JLABS, Johnson & Johnson
 

Kate Brunson

Category Manager Speciality Supplements
Whole Foods Market

Kate Brunson

Category Manager Speciality Supplements
Whole Foods Market

Kate Brunson

Category Manager Speciality Supplements
Whole Foods Market
 

Kevin Honaker

CEO
BiomeSense

Kevin Honaker is co-founder and CEO of BiomeSense, an early stage life sciences startup developing a novel biosensor that enables continuous gut microbiome tracking in the home. Kevin has worked in health care for the past 7 years and is passionate about identifying, developing and commercializing new technologies that can improve health. Prior to joining BiomeSense, he led operations for PrescriptIQ, a pharmacogenomics startup, primarily responsible for strategic planning, finance, and product development.

Kevin Honaker

CEO
BiomeSense

Kevin Honaker

CEO
BiomeSense

Kevin Honaker is co-founder and CEO of BiomeSense, an early stage life sciences startup developing a novel biosensor that enables continuous gut microbiome tracking in the home. Kevin has worked in health care for the past 7 years and is passionate about identifying, developing and commercializing new technologies that can improve health. Prior to joining BiomeSense, he led operations for PrescriptIQ, a pharmacogenomics startup, primarily responsible for strategic planning, finance, and product development. Kevin earned an MBA with honors from the University of Chicago Booth School of Business.

 

Len Monheit

Managing Partner
Trust Transparency Center

A recognized industry analyst and thought leader, Len Monheit has over 20 years experience in the natural products and dietary supplement industry, with over 15 years background in digital media. Monheit has participated in dozens of speaking engagements across four continents, talking about best business practices, industry trends across the health and wellness industries, and success factors for international business development.

Len Monheit

Managing Partner
Trust Transparency Center

Len Monheit

Managing Partner
Trust Transparency Center

A recognized industry analyst and thought leader, Len Monheit has over 20 years experience in the natural products and dietary supplement industry, with over 15 years background in digital media. Monheit has participated in dozens of speaking engagements across four continents, talking about best business practices, industry trends across the health and wellness industries, and success factors for international business development.

With a background in Biopharma and biotechnology, and as General Manager of a contract research and analytical lab, Monheit, in 1999, co-founded NPIcenter, which grew over the subsequent 8 years, to be the largest online media enterprise in the North American Natural Products industry. Selling that to Penton Media’s New Hope Natural Media in 2006, Monheit joined Penton/New Hope as digital media director, ingredient portfolio manager, market leader and ultimately Executive Director of Strategic Business Development.

Taking on the role of General Manager, US, with UK-based William Reed Business Media, Monheit, over three years, introduced two new annual conferences to the US (Food Vision and Probiota) and was responsible for a tradeshow launch (The Healthy & Natural Show) in Chicago in May of 2016. Monheit had responsibility for all of William Reed’s activities in the Americas, including FoodNavigator-USA, NutraIngredients-USA, as well as Pharma and Cosmetics publications, in addition to international partnerships and growth projects.

 

Michael Bush

Co-Founder
GrowthWays

Mike has more than 25 years of experience leading venture-backed businesses in the natural products, healthcare and bioinformatics industries. As president and CEO of probiotic innovator Ganeden, Michael grew the market of the company’s patented ingredient to over 65 countries and more than 1,000 SKUS, culminating with the 2017 merger with Kerry, Inc. Additionally, he founded a national business growth consultancy firm, co-founded a national biomedical services firm and led acquisitions and merger activities for a global medical services company.

Michael Bush

Co-Founder
GrowthWays

Michael Bush

Co-Founder
GrowthWays

Mike has more than 25 years of experience leading venture-backed businesses in the natural products, healthcare and bioinformatics industries. As president and CEO of probiotic innovator Ganeden, Michael grew the market of the company’s patented ingredient to over 65 countries and more than 1,000 SKUS, culminating with the 2017 merger with Kerry, Inc. Additionally, he founded a national business growth consultancy firm, co-founded a national biomedical services firm and led acquisitions and merger activities for a global medical services company.

 

Mike Rogers

CEO
Troo Foods

Mike Rogers

CEO
Troo Foods

Mike Rogers

CEO
Troo Foods
 

Nalin Siriwardhana

Program Manager Nutritional Sciences
Church & Dwight

Nalin Siriwardhana

Program Manager Nutritional Sciences
Church & Dwight

Nalin Siriwardhana

Program Manager Nutritional Sciences
Church & Dwight
 

Momo Vuyisich

CSO
Viome

Momo Vuyisich

CSO
Viome

Momo Vuyisich

CSO
Viome
 

Olaf Larsen

Science Manager, and Assistant Professor
Yakult, and VU University Amsterdam

Talk to me about… your research 

I studied chemistry at the VU University Amsterdam, where I progressed to obtain a PhD in biophysics from the same university.

Following my postdoctoral research in New York City and Amsterdam, I began my career within the industry. I worked for both ASML, and TNO, and as a life sciences consultant within various organizations.

Since 2012, I've headed the science department at Yakult Nederland, and since 2016, I have been a part time assistant professor at the VU University.

Olaf Larsen

Science Manager, and Assistant Professor
Yakult, and VU University Amsterdam

Olaf Larsen

Science Manager, and Assistant Professor
Yakult, and VU University Amsterdam

Talk to me about… your research 

I studied chemistry at the VU University Amsterdam, where I progressed to obtain a PhD in biophysics from the same university.

Following my postdoctoral research in New York City and Amsterdam, I began my career within the industry. I worked for both ASML, and TNO, and as a life sciences consultant within various organizations.

Since 2012, I've headed the science department at Yakult Nederland, and since 2016, I have been a part time assistant professor at the VU University.

My research focuses on the valorization of microbiota management as well as mathematical simulations of the gut microbiota.

 

Rend Al-Mondhiry

Senior Counsel
Amin Talati

Rend Al-Mondhiry advises the dietary supplement, food, cosmetic, and over-the-counter medicine industries on a broad range of regulatory and compliance matters. She is committed to helping companies responsibly develop and market products, drawing on her years of experience advising the nation’s leading dietary supplement and food companies on complex ingredient and labeling issues.

Rend Al-Mondhiry

Senior Counsel
Amin Talati

Rend Al-Mondhiry

Senior Counsel
Amin Talati

Rend Al-Mondhiry advises the dietary supplement, food, cosmetic, and over-the-counter medicine industries on a broad range of regulatory and compliance matters. She is committed to helping companies responsibly develop and market products, drawing on her years of experience advising the nation’s leading dietary supplement and food companies on complex ingredient and labeling issues.

Rend’s practice focuses on reviewing product labeling, ingredients, and advertising to determine compliance with federal and state regulations, and assisting companies in matters before the Food and Drug Administration (FDA), Federal Trade Commission (FTC), and National Adverting Division (NAD). She also advises clients on compliance with California’s Proposition 65, U.S. Customs issues, class action defense strategies, and FDA matters including Warning Letters, recalls, detentions, seizures, and import alerts.

 

Richard Cleland

Assistant Director
Federal Trade Commission

Mr. Cleland joined the Federal Trade Commission’s Division of Advertising Practices in 1991. In 1996, Mr. Cleland was appointed Assistant to the Director of the Bureau of Consumer Protection and, in 1998, he was appointed Assistant Director of the Division of Service Industry Practices.

Richard Cleland

Assistant Director
Federal Trade Commission

Richard Cleland

Assistant Director
Federal Trade Commission

Mr. Cleland joined the Federal Trade Commission’s Division of Advertising Practices in 1991. In 1996, Mr. Cleland was appointed Assistant to the Director of the Bureau of Consumer Protection and, in 1998, he was appointed Assistant Director of the Division of Service Industry Practices.

He currently serves as Assistant Director of the Division of Advertising Practices. His primary area of expertise is the advertising and marketing of health-related products and services. He also supervises many of the Commission’s health fraud and weight-loss product and service law enforcement initiatives.

Mr. Cleland supervised the FTC’s review of the Endorsement and Testimonial Guides and the revision of the FTC’s guidance on making effective disclosures on the Internet and other digital platforms (.com Disclosures). Recent projects have included social media marketing and native advertising.

 

Sean O'Sullivan

Managing Partner
SOSV

Sean O’Sullivan is managing partner of SOSV, the world-leading “Accelerator VC”. SOSV invests $50 million per year and backs more than 150 new startups annually through its accelerators. Recognized in 2017 as the world’s #1 most active global early stage investor and the #2 most active global seed investor*, SOSV is also the #1 most active investor in hardware and life sciences, helping startups get further and go faster.

 

* Crunchbase: "Global Innovation Investment Report - 2016 Year in Review"

Sean O'Sullivan

Managing Partner
SOSV

Sean O'Sullivan

Managing Partner
SOSV

Sean O’Sullivan is managing partner of SOSV, the world-leading “Accelerator VC”. SOSV invests $50 million per year and backs more than 150 new startups annually through its accelerators. Recognized in 2017 as the world’s #1 most active global early stage investor and the #2 most active global seed investor*, SOSV is also the #1 most active investor in hardware and life sciences, helping startups get further and go faster.

 

* Crunchbase: "Global Innovation Investment Report - 2016 Year in Review"

 

Sunny Jain

CEO
Sun Genomics

Sunny Jain

CEO
Sun Genomics

Sunny Jain

CEO
Sun Genomics
 

Ted Jin

CEO
DoseBiome

Ted Jin

CEO
DoseBiome

Ted Jin

CEO
DoseBiome
 

Terry Tormey

CEO
Kibow Biotech

Terrence “Terry” Tormey is CEO at Kibow Biotech, Inc., Pennsylvania, a 21-year old R&D company, which is arguably the pioneering company focused on the Gut Microbiome for a variety of serious illnesses.

Having launched and/or supported dozens of Rx products and scores of non-prescription products Mr. Tormey is an expert in Healthcare Marketing within the US and Global BioPharma Industry.

Terry Tormey

CEO
Kibow Biotech

Terry Tormey

CEO
Kibow Biotech

Terrence “Terry” Tormey is CEO at Kibow Biotech, Inc., Pennsylvania, a 21-year old R&D company, which is arguably the pioneering company focused on the Gut Microbiome for a variety of serious illnesses.

Having launched and/or supported dozens of Rx products and scores of non-prescription products Mr. Tormey is an expert in Healthcare Marketing within the US and Global BioPharma Industry.

 

Bala Ganesan

Metagenomics
Mars

Bala Ganesan

Metagenomics
Mars

Bala Ganesan

Metagenomics
Mars
 

Dr Diana Oram

Primary Reviewer/Regulatory Project Manager
FDA

Dr Diana Oram

Primary Reviewer/Regulatory Project Manager
FDA

Dr Diana Oram

Primary Reviewer/Regulatory Project Manager
FDA
 

Noah Voreadas

Principal Scientist
GenBiome

Noah Voreadas

Principal Scientist
GenBiome

Noah Voreadas

Principal Scientist
GenBiome
 

Raja Sivamani, M.D., M.S., A.P.

Adjunct Associate Professor of Clinical Dermatology
UC Davis

Dr. Raja Sivamani is a board-certified dermatologist and practices as an integrative dermatologist at Pacific Skin Institute. He is an Adjunct Associate Professor of Clinical Dermatology at the University of California, Davis and Director of Clinical Research and the Clinical Trials Unit. He is also an Adjunct Assistant Professor in the Department of Biological Sciences at the California State University, Sacramento and an Associate Professor of Dermatology at California Northstate University, College of Medicine.

Raja Sivamani, M.D., M.S., A.P.

Adjunct Associate Professor of Clinical Dermatology
UC Davis

Raja Sivamani, M.D., M.S., A.P.

Adjunct Associate Professor of Clinical Dermatology
UC Davis

Dr. Raja Sivamani is a board-certified dermatologist and practices as an integrative dermatologist at Pacific Skin Institute. He is an Adjunct Associate Professor of Clinical Dermatology at the University of California, Davis and Director of Clinical Research and the Clinical Trials Unit. He is also an Adjunct Assistant Professor in the Department of Biological Sciences at the California State University, Sacramento and an Associate Professor of Dermatology at California Northstate University, College of Medicine. He engages in clinical practice as well as both clinical and translational research that integrates bioengineering, nutrition, cosmetics, and skin biology. With training in both Allopathic and Ayurvedic medicine, he takes an integrative approach to his patients and in his research. He has published over 100 peer-reviewed research manuscripts, 10 textbook chapters, and a textbook entitled Cosmeceuticals and Active Cosmetics, 3rd Edition with a passion for expanding the evidence and boundaries of integrative medicine and our understanding of the gut-skin axis.

 

Official job titles:

Dermatologist, Pacific Skin Institute

Adjunct Associate Professor of Clinical Dermatology, UC Davis

Assistant Professor, CSU - Sacramento

Associate Professor of Dermatology, CNU College of Medicine

Event Partners

Become a Sponsor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at partner@kisacoresearch.com.

The Agenda

The pre and probiotics market is growing at a staggering pace, consumer interest in gut health has skyrocketed and the industry is forecast to reach $64bn USD by 2022. Combined with substantial improvements in microbiome R&D, organizations in this space are booming. Please use the form to download the agenda for the Microbiome Consumer Nutrition Congress, and see the high caliber of speakers we have for the event.

Microbiome Consumer Nutrition Congress

Download Full Agenda

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Worldpay:
Thursday, May 2, 2019 to Friday, July 19, 2019
Academics, Clinicians, Students & Post-Doctural Researchers
$699
Super Early Bird
Main 2 Day Conference - All Sessions
Thursday, May 2, 2019 to Friday, July 19, 2019
Independent brands & Biotechs (under $10m revenue)
$799
Super Early Bird
Main 2 Day Conference - All Sessions
Thursday, May 2, 2019 to Friday, July 19, 2019
Pharma Brands (Over $10m revenue)
$1,499
Super Early Bird
Main 2 Day Conference - All Sessions
Thursday, May 2, 2019 to Friday, July 19, 2019
Vendors/Ingredient Manufacturers
$1,899
Super Early Bird
Main 2 Day Conference - All Sessions
Saturday, July 13, 2019 to Friday, August 9, 2019
Vendor/Ingredient Manufacturers
$1,999
Early Bird Pricing
Main 2 Day Conference - All Sessions
Preparing registration...

Venue

1625 Post St, San Francisco, California, United States, 94115

Hotel Kabuki
Just outside the front door of Hotel Kabuki lies the legendary Fillmore District. San Francisco’s most iconic attractions, including Union Square, the Golden Gate Bridge, and Lombard Street, are just a short walk away when you stay in this newly renovated and elegant space.

Book a Team to Save More!

Industry Rates Only: Team discounts cannot be combined with any other discount or offer

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

Payment Terms for the the Microbiome Conference:

  • Please note that a $79 processing fee will apply to any invoices requested.
  • * You must email us a signed letter from the Hospital / Clinic Supervisor or University / Laboratory with confirmation of your status upon payment
  • All Prices are in USD
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • All discount offers cannot be combined with any other offer.
  • Please view our Cancellation Policy.

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.